B+
Bull case
20%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-04-06 · RankAlpha Sentiment AI
RLYB
RallybioFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-06 · RankAlpha Sentiment AI
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-04-06 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+2.0
Score
AI commentary
Market tone is cautious-to-neutral: recent positive Phase 1 data created hopeful headlines but disclosure of the CMO departure increased execution risk [#IR-undated] [#8-K-2026-03-31]. Analyst coverage is thin with consensus near the current price, suggesting limited conviction among sell-side participants [#SERP-1] [#SERP-3].
RankAlpha Sentiment AI - 2026-04-06
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-07-05catalystNear-term leadership gap after Chief Medical Officer departureHigh impact
Rallybio disclosed the immediate departure of its CMO (Steven Ryder, M.D.) on 2026-03-31; this personnel change could slow clinical program execution or increase perceived execution risk in the coming quarters [#8-K-2026-03-31].
2027-04-06catalystAdvancement of RLYB116 development after positive Phase 1 dataHigh impact
Rallybio reported positive Phase 1 data for RLYB116 demonstrating complete and sustained inhibition of terminal complement; progression decisions (e.g., IND-enabling activities or partnered development) over the next 12 months could materially re-rate value if a clear path to a Phase 2 program or partner emerges [#IR-undated].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-06 • Updated nightlySource: Internal modelMethodology